Myeloid cell leukemia-1 (MCL1) is an anti-apoptotic member of the BCL2 family that is deregulated in various solid and hematological malignancies. However, its role in the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL) is unclear. We analyzed gene expression profiling data from 350 DLBCL patient samples and detected that activated B-cell-like (ABC) DLBCLs express MCL1 at significantly higher levels compared with germinal center B-cell-like DLBCL patient samples (P ¼ 2.7 Â 10 À 10 ). Immunohistochemistry confirmed high MCL1 protein expression predominantly in ABC DLBCL in an independent patient cohort (n ¼ 249; P ¼ 0.001). To elucidate molecular mechanisms leading to aberrant MCL1 expression, we analyzed array comparative genomic hybridization data of 203 DLBCL samples and identified recurrent chromosomal gains/amplifications of the MCL1 locus that occurred in 26% of ABC DLBCLs. In addition, aberrant STAT3 signaling contributed to high MCL1 expression in this subtype. Knockdown of MCL1 as well as treatment with the BH3-mimetic obatoclax induced apoptotic cell death in MCL1-positive DLBCL cell lines. In summary, MCL1 is deregulated in a significant fraction of ABC DLBCLs and contributes to therapy resistance. These data suggest that specific inhibition of MCL1 might be utilized therapeutically in a subset of DLBCLs.
INTRODUCTION
Diffuse large B-cell lymphomas (DLBCLs) account for B30-40% of all malignant lymphoma cases in adults. DLBCL is considered as a heterogeneous diagnostic category with respect to morphology, biology and clinical presentation. 1 Several gene expression profiling studies supported this view, as different molecular subtypes of DLBCL, termed as germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL and primary mediastinal B-cell lymphoma, could be distinguished. [2] [3] [4] [5] [6] These subgroups not only differ with respect to their gene expression profile, but also they have significantly different overall survival rates. 3, 7, 8 GCB DLBCL and primary mediastinal B-cell lymphoma patients respond relatively favorable to a combined approach of the anti-CD20 antibody rituximab and the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP). 9, 10 In contrast, ABC DLBCL patients are characterized by adverse survival. 9 Inhibition of apoptosis significantly contributes to the molecular pathogenesis of various forms of cancer and additionally mediates therapy resistance. 11 Apoptosis can be initiated through extrinsic death receptors or intrinsic mitochondrial pathways. 12 The extrinsic apoptotic pathway is triggered by ligation of death receptors such as Fas or TNF-receptor 1. 12 In contrast, the mitochondrial pathway is regulated by BCL2 family proteins. 13 The BCL2 family regulates cell survival and can either promote or inhibit cell death. BCL2 family members share regions of homology called BCL2 homology domain and can, according to their structure and function, be classified into three subgroups: (1) anti-apoptotic members (BCL2, BCL-XL, BCL-W, BCL2A1 and myeloid cell leukemia-1 (MCL1)) (2) multidomain pro-apoptotic members (Bax and Bak) and (3) BH3-only pro-apoptotic proteins (Bim, Bad, BMF, NOXA, HRK, PUMA, Bik and Bid). 12 The relative expression levels between these different subgroups are critical for cell fate. 14 MCL1 exerts an anti-apoptotic function by binding and sequestering the pro-apoptotic members Bak and Bax that can form pores in the mitochondrial membrane leading to cytochrome c release into the cytoplasm and thus activating downstream caspases. Additionally, MCL1 interacts with several BH3-only pro-apoptotic proteins that act to induce oligomerization of Bak and Bax. 15 MCL1 has been shown to be deregulated in various solid and hematological malignancies such as non-small cell lung cancer, hepatocellular carcinoma, acute myeloid and acute lymphoblastic leukemia as well as in multiple myeloma. [16] [17] [18] [19] [20] [21] The role of MCL1 in the molecular pathogenesis of DLBCL has not yet been clarified. Interestingly, MCL1 transgenic mice developed lymphomas at a high frequency. Histologically, the majority of cases represented DLBCL, implicating a role of MCL1 in the biology of this entity. 22 In the present study, we investigated the role of MCL1 in the molecular pathogenesis of different DLBCL subtypes. We detected that MCL1 is expressed on both mRNA and protein levels significantly higher in ABC compared with GCB DLBCL. This aberrant expression is caused by both MCL1 locus gain/amplification and constitutive activation of the STAT3 pathway. Knockdown of MCL1 or treatment with the BH3-mimetic obatoclax (GX15-070) was toxic to MCL1-positive cell lines, implicating a role of MCL1 in the biology of a subgroup of DLBCLs as well as suggesting that MCL1 inhibition might represent a novel therapeutic approach in these lymphomas.
MATERIALS AND METHODS

Gene expression profiling
Gene expression data from 414 patients who were treated with either CHOP (n ¼ 181) or R-CHOP-like immunochemotherapy (n ¼ 233) and profiled using Affymetrix HG-U133 Plus 2.0 microarrays by Lenz et al., 9 were obtained from the Gene Expression Omnibus (GEO) of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/geo; GSE10846). Patients were classified into ABC DLBCL, GCB DLBCL and unclassified DLBCL according to Lenz et al. 9 Primary mediastinal B-cell lymphoma cases were excluded from this analysis.
Cell culture, retroviral constructs and transduction Human DLBCL cell lines were cultured in RPMI-1640 with 10% fetal calf serum except for OCI-Ly3, OCI-Ly10, TMD8, OCI-Ly1, OCI-Ly2 and OCI-Ly7 that were cultured in IMDM (Iscove's modified Dulbecco medium) supplemented with either 20% human plasma or 10% fetal calf serum.
For efficient retroviral transductions, cell lines were engineered to express the murine ecotropic receptor as previously described. 23 Additionally, these cell lines were engineered to express the bacterial tetracycline repressor allowing doxycycline-inducible short-hairpin RNA (shRNA) or MCL1 complementary DNA (cDNA) expression. 23 shRNAmediated RNA interference was performed as described. 23, 24 The targeting sequence of MCL1 shRNAs #1 and #2 was GGGCTCTGATT GGGCAATACT and GGGACTGGCTAGTTAAACAAAG, respectively. Each shRNA experiment was completely reproduced at least three times for each cell line. As a positive shRNA control, we used previously described shRNAs against CARD11 for ABC DLBCL 23 and MYC for GCB DLBCL cell lines. 25 As a negative control, we used a previously described SC4 shRNA. 25 For the shRNA rescue experiment, cell clones of U2932 that expressed an MCL1 isoform 1 cDNA (NM_021960.4) were created. The rescue experiment was reproduced three times.
Array comparative genomic hybridization
Genomic DNA from DLBCL cell lines was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). Normal male genomic DNA was used as reference. DNA fragmentation, labeling and co-hybridization to Human CGH 3 Â 720K Whole-Genome Tiling arrays (NimbleGen, Madison, WI, USA) containing 722 521 probes was performed as previously described. 26 The array comparative genomic hybridization (aCGH) data has been deposited in the GEO database (GSE43272).
The aCGH data from 203 DLBCL patient samples were obtained from GEO through the GEO accession number GSE11318. 26 164 DLBCL samples of this cohort were part of the CHOP gene expression cohort mentioned above (GSE10846). In addition, aCGH was performed on 39 DLBCL patient samples that were not part of the gene expression cohort. The detailed analysis algorithm is described in Supplementary Material and Methods.
Immunohistochemistry
Previously utilized tissue microarrays with 249 primary DLBCLs were used for the present study. 27 Cases were classified as GCB or non-GCB-like DLBCL applying the Tally algorithm. 28 Primary mediastinal B-cell lymphoma cases were excluded from our analyses. Staining for MCL1 was established using the primary antibody SC-819 (Santa Cruz, Santa Cruz, CA, USA) at a dilution of 1:100. 29, 30 To differentiate MCL1-positive and -negative DLBCL cases, we applied the commonly used cutoff value of 30% positive cells. Using this cutoff, we were able to reproduce expression levels detected by western blotting in various DLBCL cell lines (see Results).
Immunohistochemistry was performed on an automated immunostainer (Benchmark; Ventana/Roche, Tucson, AZ, USA). Antigen retrieval was achieved by mild cell conditioning treatment (CC1; Ventana/Roche) followed by incubation for 32 min, signal amplification and visualization (amplifier and chromogen ultraview universal diaminobenzidine). At last, slides were counterstained with hematoxylin and bluing reagent. MCL1 staining was established by two expert hematopathologists on tonsils and cell pellets of DLBCL cell lines that were previously tested for MCL1 expression by western blot. The observed staining pattern was cytoplasmic and slightly granular. The antibody staining was moderate to strong in all cases considered as MCL1 positive. A very weak non-granular cytoplasmic staining in a smaller proportion of cells was occasionally observable. Since none of the positive samples showed such a staining pattern, these weak stainings were considered as artificial and the respective cases scored as MCL1 negative. DLBCL cases were scored by counting the number of positive tumor cells out of all tumor cells on 0.2 mm 2 tissue spots and recorded in 5% steps.
Immunohistochemistry for pSTAT3 was performed as previously described. 31 Real-time quantitative PCR Relative abundance of MCL1 was determined as previously described. 26 
Western blotting
Western blotting was performed as previously described. 32 Detailed protocols are available in Supplementary Material and Methods.
Immunoprecipitation
Immunoprecipitation was performed as previously described. 32 Detailed protocols are available in Supplementary Material and Methods.
In vitro proliferation assay, JAK/STAT3 inhibitor studies and analysis of cell cycle and apoptosis Detailed protocols are available in Supplementary Material and Methods.
Statistical analysis
Comparisons of differences in continuous variables between two groups were performed using unpaired one-tailed Student's t-tests, unless stated otherwise. Relationships between two categorical variables were analyzed in a 2 Â 2 contingency table using Fisher's exact test. P-values of o0.05 were considered as statistically significant.
RESULTS
MCL1 is significantly higher expressed in ABC compared with GCB DLBCL To investigate the role of MCL1 in the pathogenesis of DLBCL subtypes, we assessed MCL1 mRNA expression levels in a gene expression data set of 350 primary DLBCL samples. 9 Our analyses revealed that ABC DLBCL tumor samples (n ¼ 167) expressed MCL1 mRNA significantly higher compared with GCB DLBCLs (n ¼ 183; P ¼ 2.7 Â 10 À 10 ; two-tailed Student's t-test; Figure 1a ). Interestingly, we detected that while many ABC DLBCLs have very high MCL1 expression, others express MCL1 at low levels ( Figure 2d ). Similarly, we were able to identify a small subgroup of GCB DLBCLs with high MCL1 mRNA levels ( Figure 2d) .
Next, we analyzed, if increased MCL1 mRNA levels are translated into high protein expression. To this end, we performed immunohistochemistry for MCL1 in an independent cohort of 249 DLBCL patient samples (Figure 1b-g ). Detection of MCL1 by immunohistochemistry was established by staining MCL1-positive and -negative DLBCL cell lines as well as normal tonsils. The ABC DLBCL cell lines U2932, TMD8, OCI-Ly3 and OCI-Ly10 and the GCB DLBCL cell line BJAB expressed MCL1 by immunohistochemistry, while all other cell lines (OCI-Ly1, OCI-Ly2 and HT) did not express detectable MCL1 levels (Figure 1b and c) . As shown below, the results of the immunohistochemistry confirmed our western blot results with the exception of BJAB that showed only weak MCL1 expression by western blotting. In all, 218 DLBCL samples (88%) were evaluable for MCL1 staining. Thirty-five cases (18%) were completely negative for MCL1. In the remaining samples, 5-80% of lymphoma cells expressed MCL1 (mean 25%; median 15%; Figure 1e and f). Applying the commonly used cutoff of 430% of positive lymphoma cells to differentiate MCL1 positive from negative cases, only 17/67 (25%) of GCB DLBCLs were MCL1 positive. In contrast, 72/151 (48%) non-GCB DLBCL cases expressed MCL1 (P ¼ 0.001; Fisher's exact test; Figure 1g ), suggesting that increased mRNA levels are translated into high protein expression and furthermore confirming that MCL1 is detectable significantly more frequently in ABC DLBCL.
MCL1 is deregulated by chromosomal gain/amplification and constitutive activation of STAT3 To investigate whether established DLBCL cell lines represent adequate models for functional analyses, we screened 12 DLBCL cell lines for MCL1 expression by western blotting (Figure 1h ). Four out of five ABC DLBCL cell lines had detectable MCL1 expression (U2932, OCI-Ly3, OCI-Ly10 and TMD8), whereas only one GCB DLBCL line (SUDHL-10) expressed MCL1 at comparable levels (P ¼ 0.045; Fisher's exact test; ABC DLBCL vs GCB DLBCL cell lines) confirming that these cell lines represent adequate functional models. In the remaining ABC (HBL-1) and GCB DLBCL cell lines (BJAB, HT, OCI-Ly1, OCI-Ly2, OCI-Ly7 and Karpas422), MCL1 expression was either low or not detectable (Figure 1h ). Interestingly, the five cell lines with detectable MCL1 protein expression (U2932, OCI-Ly3, OCI-Ly10, TMD8 and SUDHL-10) had significantly higher mRNA expression levels determined by gene expression profiling compared with cell lines without protein expression (P ¼ 0.03; one-tailed t-test).
To analyze, if DLBCL cell lines are characterized by expression of other anti-apoptotic family members, we determined the expression status for BCL2 and BCL-XL by western blotting (Supplementary Figure 1) . As expected, BCL2 and the known nuclear factor-kappa B (NF-kB) pathway target gene BCL-XL were expressed in all ABC DLBCL cell lines as this subtype is characterized by BCL2 amplifications and constitutive activation of NF-kB. 1, 26 In contrast, only the GCB DLBCL cell line OCI-Ly2 that harbors a BCL2 translocation showed high BCL2 expression. 33 Interestingly, the majority of GCB DLBCL cell lines had detectable levels of BCL-XL. These data implicate that predominantly ABC DLBCL cell lines are characterized by deregulation of several members of the anti-apoptotic BCL2 family (Supplementary Figure 1) .
To elucidate, if copy number alterations might contribute to increased MCL1 expression, we performed aCGH in our panel of 12 DLBCL cell lines. In the ABC DLBCL cell line U2932 as well as in the GCB DLBCL line SUDHL-10, we detected a high level amplification of the MCL1 locus (Figures 2a and b) . Both lines are characterized by strong MCL1 expression, as shown by western blot analysis (Figure 1h ). In the MCL1-positive ABC DLBCL cell line OCI-Ly3 a gain of the MCL1 locus was detectable. In contrast, the other cell lines did not show any genetic aberrations.
To clarify, if genomic amplifications also occur in primary DLBCL patient samples, we analyzed the MCL1 locus for chromosomal gains/amplifications in a previously published data set of 203 DLBCL patient samples that were investigated by aCGH. 26 Gain/ amplification of the MCL1 locus on chromosome 1q21 was detectable in 25.7% of ABC DLBCLs (Figure 2c and d) . In contrast, our analyses revealed that only 12.5% of GCB DLBCLs showed this abnormality (P ¼ 0.034; Fisher's exact test). In ABC DLBCL, gain or amplification of the MCL1 locus significantly increased MCL1 mRNA expression compared with cases without this abnormality (P ¼ 0.004; one-tailed Student's t-test; Figure 2d ). In contrast, in GCB DLBCL copy number gain did not increase expression of MCL1 (P ¼ 0.85; one-tailed Student's t-test; Figure 2d) . Thus, MCL1 expression is deregulated by recurrent copy number abnormalities only in ABC DLBCL (Figure 2d) .
Previous work suggested that inhibition of STAT3 decreases MCL1 expression. [34] [35] [36] To assess, if constitutive STAT3 signaling is involved in the regulation of MCL1 expression in DLBCLs with and without MCL1 amplifications, we treated MCL1-positive cell lines with a pan JAK inhibitor (JAK-Inhibitor I) that downregulates STAT3 signaling and in a second experiment with a direct STAT3 inhibitor (WP1066) (Figure 2e; Supplementary Figure 2) . Our analyses revealed that inhibition of STAT3 downregulates MCL1 protein only in a subset of cell lines. In TMD8 and OCI-Ly10 that do not have an MCL1 gain/amplification, MCL1 expression seems to be regulated by STAT3 signaling. In OCI-Ly3 cells that harbor an MCL1 locus gain, a decrease in MCL1 expression following STAT3 inhibition was detectable, implying that different molecular mechanisms deregulating MCL1 can occur in the same sample (Figure 2e; Supplementary Figure 2) . In contrast, in U2932 and SUDHL-10 that are characterized by high level MCL1 amplifications (Figures 2a and b) , inhibition of STAT3 did not alter MCL1 protein expression (Figure 2e; Supplementary Figure 2 ). These results imply that different molecular mechanisms contribute to aberrant MCL1 expression in DLBCL.
Previous work showed that predominantly ABC DLBCLs are characterized by constitutive activation of STAT3. 34, 35 Thus to investigate, if activation of STAT3 also contributes to high MCL1 expression in primary DLBCL patient samples, we determined the pSTAT3 expression levels in our immunohistochemistry cohort in non-GCB DLBCL patient samples (Figure 2f and g ). In all, 29 out of 43 (67.4%) MCL1-positive cases, stained positive for pSTAT3. In contrast, only 22 out of 49 (44.9%) MCL1-negative cases showed STAT3 activation (P ¼ 0.037; Fisher's exact test). These results suggest that constitutive activation of STAT3 contributes to MCL1 deregulation in primary DLBCL samples.
Downregulation of MCL1 induces cell death and apoptosis
To investigate the functional significance of MCL1 in DLBCL, we knocked down its expression using retroviruses expressing shRNAs that mediate RNA interference (Figure 3a ; Supplementary Figure 3a) . We identified two different MCL1 shRNAs that significantly decreased MCL1 expression on both mRNA (Po0.01; one-tailed Student's t-test) and protein level (Figures 3b  and c) . Knockdown of MCL1 was toxic to the four ABC DLBCL cell lines that express MCL1 (U2932, OCI-Ly3, OCI-Ly10 and TMD8) as well as to the MCL1-positive GCB DLBCL cell line SUDHL-10 ( Figure 3a) . In contrast, these shRNAs showed no toxicity for cell lines without MCL1 expression, whereas control shRNAs were toxic to all cell lines (Figure 3a; Supplementary Figure 3a) . To demonstrate that MCL1 shRNA toxicity was due to MCL1 knockdown, we expressed a cDNA containing only the coding region of MCL1 isoform 1 in U2932 to perform a rescue experiment. Using an shRNA targeting the 3'-untranslated region of endogenous MCL1, we demonstrated that cells expressing the exogenous MCL1 cDNA could be rescued from shRNA toxicity. In contrast, MCL1 knockdown was toxic to control U2932 cells (Figure 3d) .
To obtain additional insights into the nature of the growth inhibitory effect of MCL1 knockdown, we analyzed whether changes in cell cycle or apoptosis were induced in the two ABC DLBCL cell lines U2932 and TMD8 by MCL1 knockdown. To this end, we utilized cells that were transduced with both MCL1 shRNAs to induce optimal MCL1 knockdown. Downregulation of MCL1 did not induce a cell-cycle arrest (data not shown). However, we detected a sub-G1 peak in both U2932 and TMD8 suggesting induction of apoptosis (Po0.001; one-tailed Student's t-test; Figure 4a ; Supplementary Figure 3b) . Annexin V staining confirmed increased apoptosis following MCL1 downregulation in both cell lines, implying that MCL1 downregulation significantly induces apoptosis in DLBCL (Po0.01; one-tailed Student's t-test; Figure 4b and Supplementary Figure 3c ).
MCL1 interacts with Bak and Bim in DLBCL Next, we assessed by which interactions MCL1 inhibits apoptosis in DLBCL. It is known that MCL1 binds and sequesters proapoptotic members of the BCL2 family such as Bak or Bax. 15 We performed immunoprecipitations using an MCL1 antibody and detected an interaction with Bak, Bim and NOXA (Figure 4c ). In contrast, we could not detect an interaction with other members of the BCL2 family including Bad, Bax, PUMA or Bid (Figure 4c ). These data implicate that DLBCLs utilize MCL1 to inactivate Bak and Bim to prevent apoptosis and sustain cell survival.
MCL1 mediates resistance to chemotherapeutic agents MCL1 has an important role in conferring resistance to conventional chemotherapy in various tumors. [16] [17] [18] [19] [20] [21] To elucidate whether MCL1 contributes to therapy resistance in DLBCL, we expressed an MCL1 cDNA in the MCL1-deficient GCB DLBCL cell line HT and subsequently treated these cells with chemotherapeutic agents that are commonly used for the treatment of DLBCL patients (Figure 5a ). HT cells were analyzed 24 h after treatment with doxorubicin, vincristine and etoposide by viability assay. Ectopic expression of MCL1 decreased sensitivity of HT cells to these agents (Figure 5a ). Using 4 mM of doxorubicin, cell viability was enhanced from 32% in MCL1-negative cells to 72% (Po0.001; one-tailed Student's t-test) in HT cells that expressed MCL1. In line, at a concentration of 500 mM of vincristine, 83% of MCL1-positive HT cells were alive in comparison with only 33% (Po0.001; onetailed Student's t-test) that did not express MCL1. A similar effect was observed when etoposide was used (Figure 5a ).
Based on these findings, we assessed whether MCL1 knockdown enhances chemosensitivity of U2932 and TMD8 that both express MCL1. To obtain optimal MCL1 knockdown, both cell lines were engineered to express both MCL1 shRNAs. Following shRNA induction, these cells were subsequently treated with doxorubicin, etoposide or vincristine (Figure 5b ). Twenty-four hours after treatment with these chemotherapeutic agents, cell viability was analyzed by CellTiter-Glo Luminescent Cell Viability Assay (Figure 5b ). To detect synergistic effects, the results were normalized to the shRNA expressing cell line without inhibitor. The combination of chemotherapy and MCL1 knockdown was significantly more toxic to U2932 and TMD8-with the exception of doxorubicin in U2932-implying that MCL1 knockdown enhances chemosensitivity in DLBCL and therefore might represent a promising therapeutic target (Figure 5b ).
MCL1 expressing cell lines are sensitive to obatoclax
To test whether MCL1 expressing DLBCL cell lines respond more sensitive to MCL1 inhibition compared with cells that do not express MCL1, we treated various DLBCL cell lines with obatoclax (GX15-070) (Figure 5c ). Obatoclax is a small molecule that binds the BH3-binding site of BCL2 family members and has been shown to overcome MCL1-mediated resistance to apoptosis in various forms of cancer by interfering with the interaction of MCL1 and Bak. 37 To this end, we treated various MCL1-positive and -negative DLBCL cell lines with obatoclax for 2 days and evaluated the effects on cell viability (Figure 5c ). Two control cell lines (HBL-1 and Karpas422) with low MCL1 expression were insensitive to obatoclax treatment up to 125 nM, which is consistent with the notion that these cell lines do not depend on MCL1 function. In contrast, all cell lines that express MCL1 were sensitive to obatoclax (Figure 5c ) with SUDHL-10 and U2932 both harboring genomic amplifications and high MCL1 expression being the most sensitive cell lines.
To further investigate the nature of cell death, we analyzed whether apoptosis was induced by obatoclax. As expected, we detected a sub-G1 peak after 48 h of obatoclax treatment in U2932 indicating a significant induction of apoptosis (Po0.001; one-tailed Student's t-test; Figure 5d and e). Significant increase in early and late apoptosis was confirmed by Annexin V staining (Po0.001; one-tailed Student's t-test; Figure 5f ). These data implicate that inhibition of MCL1 function UTR) ), from toxicity. Live cells were enumerated as described in (a). Representative results from at least three independent replicates are shown. **Po0.01, ***Po0.001.
might represent an effective therapeutic approach in DLBCLs that express MCL1.
DISCUSSION
Despite recent improvements in prognosis, mainly due to the addition of the anti-CD20 antibody rituximab to conventional chemotherapy, a substantial fraction of DLBCL patients will succumb to their disease. 9 Especially patients with refractory disease or those who experience early relapse are characterized by poor prognosis. 38 Thus, novel therapeutic strategies are critically warranted. Interestingly, many ABC DLBCLs are characterized by aberrant expression of different anti-apoptotic BCL2 family members. BCL2 itself is significantly upregulated in this lymphoma subtype by both constitutive activation of the oncogenic NF-kB pathway and by genomic amplifications of the BCL2 locus on chromosome 18q21. 26, 39, 40 BCL-XL and BCL2A1 are known NF-kB target genes and therefore are significantly upregulated in ABC DLBCL (Supplementary Figure 1) . Thus, it seems conceivable that ABC DLBCLs have various alterations in their apoptotic machinery that might mediate therapy resistance.
Previous work has shown that MCL1 contributes to inhibition of apoptosis and resistance to conventional treatment in various solid and hematological cancers. [16] [17] [18] [19] [20] [21] Interestingly, MCL1 transgenic mice develop lymphomas at a high incidence of 485%.
22 A large fraction of these lymphomas resemble DLBCL, indicating that aberrant MCL1 expression is involved in the biology of this lymphoma subtype. Using both gene expression profiling and immunohistochemistry, we have discovered that MCL1 is expressed at significantly different levels in ABC and GCB DLBCL. Unexpectedly, mRNA expression levels were significantly higher in the ABC subtype compared with GCB DLBCLs. This higher expression was confirmed on protein level in an independent cohort of 218 DLBCL samples by immunohistochemistry. In total, 89/218 cases (41%) showed strong MCL1 expression. Roughly 50% of non-GCB DLBCLs were MCL1 positive, whereas MCL1 expression was detectable in only 25% of GCB DLBCLs. Interestingly, we detected on both mRNA and protein level that while many ABC DLBCLs have very high MCL1 expression, others either do not express MCL1 or are MCL1 low expressers. In contrary, a minority of GCB DLBCLs express MCL1 almost at comparable levels as ABC DLBCLs. These results indicate that oncogenic MCL1 expression is utilized by both molecular DLBCL subtypes albeit at different frequencies. Therefore, despite the fact that ABC and GCB DLBCLs are significantly different with respect to their gene expression profile, the occurrence of specific chromosomal abnormalities, and the utilization of oncogenic pathways, it is evident that certain pathogenetic events can be shared between these two subgroups.
In a previous study of 31 DLBCL patients, MCL1 expression was detectable in the majority of patients. 41 In contrast, in our study many DLBCL patients did not express significant MCL1 levels. These discrepant results might be caused by a smaller sample size that can be biased with respect to the number of included ABC and GCB DLBCLs, by the application of different antibodies and differences in staining techniques. However, our mRNA and protein expression as well as functional data strongly suggest that oncogenic MCL1 function is utilized only by a subgroup of DLBCL samples.
We identified different molecular mechanisms that contribute to aberrant MCL1 expression. The MCL1 locus was gained/ amplified significantly more frequently in ABC compared with GCB DLBCLs contributing to MCL1 upregulation in these lymphomas. MCL1 amplifications have been detected in various different cancers. 42 In DLBCL amplifications of 1q21 have previously been reported in small studies. However, the incidence of these aberrations as well as the predominant occurrence in ABC DLBCL have not been noted. 43, 44 In cell line models without amplification of the MCL1 locus, constitutive activation of the STAT3 signaling pathway contributed to MCL1 deregulation. Previous work implicated that the STAT3 signaling pathway is constitutively active predominantly in ABC DLBCL and that STAT3 inhibition downregulates MCL1 expression. [34] [35] [36] Interestingly, in one ABC DLBCL cell line both an MCL1 gain and constitutive STAT3 activation were detectable, implying that different mechanisms can be utilized by the same lymphoma cell to deregulate MCL1 expression.
Our experiments demonstrated that knockdown of MCL1 is toxic to DLBCL cell line models that express MCL1. This finding is surprising, as several anti-apoptotic BCL2 family members are deregulated in DLBCL, implying that MCL1 has a non-redundant role in the pathogenesis of DLBCL. Intriguingly, this toxic phenotype was irrespective of the molecular subtype as ABC and GCB DLBCL cell lines were selectively killed by MCL1-specific shRNAs. This finding underscores that MCL1 function can be utilized by both molecular subtypes. As expected, MCL1 knockdown induced apoptosis and our immunoprecipitation experiments showed that MCL1 can prevent apoptosis by binding and sequestering the anti-apoptotic BCL2 family member Bak. Most likely, silencing of MCL1 leads to release of Bak and induction of apoptosis. These results imply that MCL1 is critical for survival of a subset of DLBCLs. Consistently, treatment of MCL1-positive and -negative cell lines with the BH3-mimetic obatoclax demonstrated increased sensitivity of DLBCL samples that have high MCL1 expression. However, obatoclax is a pan-BCL2 family antagonist and not an MCL1-specific inhibitor. Therefore, obatoclax might show toxicity that is not only due to inhibition of MCL1 function but potentially also of other apoptotic BCL2 members.
Finally, knockdown of MCL1 increased sensitivity to several chemotherapeutic drugs that are commonly used in the treatment of DLBCL patients. Conversely, exogenous overexpression of MCL1 in an MCL1-deficient cell line significantly increased resistance to doxorubicin, vincristine and etoposide. This effect was comparable to exogenous overexpression of BCL2 (data not shown) that is also frequently deregulated in subtypes of DLBCL, suggesting that different aberrations can contribute to therapy resistance in DLBCL. Therefore, our data suggest that aberrant MCL1 expression is not only important for cell survival but that MCL1 additionally has a critical role in modifying sensitivity to chemotherapy.
Collectively, our data clearly suggest a role of MCL1 in the biology of DLBCL. We uncovered the molecular mechanisms that lead to aberrant MCL1 expression and the functional consequences of MCL1 silencing. The biological insights gained from our study might provide a perspective on future clinical trials. Determining MCL1 expression in DLBCL patients could be therapeutically relevant, as its inhibition-for example, by obatoclax or by more specific compounds in the near futuremight be beneficial for patients with high aberrant MCL1 expression. A combined approach of conventional immunochemotherapy with R-CHOP and inhibition of MCL1 might potentially overcome the therapeutic dilemma of patients that relapse early or who are primary refractory to first-line treatment.
